Hamlin, Paul

Publications

Sort by

Co-Author Network

selected publications

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. British journal of haematology. 2018 Academic Article GET IT
Times cited: 44
Treatment of Rosai-Dorfman disease with oral bexarotene: a case series. 2018 GET IT
Times cited: 2
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood cancer journal. 2018 Academic Article GET IT
Times cited: 22
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer discovery. 2017 Academic Article GET IT
Times cited: 243
Development of a Geriatric Service in a Cancer Center: Lessons Learned. Journal of oncology practice. 2017 Comment GET IT
Times cited: 20
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 54
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2016 Review GET IT
Times cited: 36
Central nervous system involvement in T-cell lymphoma: A single center experience. Acta oncologica (Stockholm, Sweden). 2016 Academic Article GET IT
Times cited: 34
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Academic Article GET IT
Times cited: 33
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma. Current oncology reports. 2015 Review GET IT
Times cited: 11
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 30
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 201
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. 2015 GET IT
Times cited: 53
Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. Journal of geriatric oncology. 2014 Conference Paper GET IT
Times cited: 50
Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. The oncologist. 2014 Academic Article GET IT
Times cited: 50
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. British journal of haematology. 2014 Academic Article GET IT
Times cited: 29
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014 Academic Article GET IT
Times cited: 46
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investigational new drugs. 2014 Academic Article GET IT
Times cited: 87
Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Editorial Article GET IT
Times cited: 5
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014 Letter GET IT
Times cited: 48
A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 36
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 163
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2011 Academic Article GET IT
Times cited: 226
Testis-isolated mantle cell lymphoma: a unique case. 2011 GET IT
Times cited: 5
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Is maintenance rituximab now ready for PRIMA-time?. Current oncology reports. 2010 Academic Article GET IT
Times cited: 2
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 269
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. British journal of haematology. 2010 Academic Article GET IT
Times cited: 80
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
Meta-analysis: making sense of maintenance rituximab?. Current oncology reports. 2009 Comment GET IT
Distress in older patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 99
Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 166
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British journal of haematology. 2009 Academic Article GET IT
Times cited: 49
A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clinical pharmacology and therapeutics. 2009 Academic Article GET IT
Times cited: 37
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 121
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. British journal of haematology. 2009 Academic Article GET IT
Times cited: 68
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 126
Do six or eight cycles work better with CHOP-14 and rituximab?. Current oncology reports. 2008 Academic Article GET IT
A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 18
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. British journal of haematology. 2007 Academic Article GET IT
Times cited: 79
Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 5
Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. Journal of the American Geriatrics Society. 2007 Academic Article GET IT
Times cited: 128
New drugs for the treatment of advanced-stage diffuse large cell lymphomas. Seminars in hematology. 2006 Review GET IT
Times cited: 10
Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. 2006 GET IT
Times cited: 24
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. British journal of haematology. 2006 Academic Article GET IT
Times cited: 104
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. British journal of haematology. 2005 Academic Article GET IT
Times cited: 109
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood. 2005 Academic Article GET IT
Times cited: 72
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 546
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. Journal of the National Comprehensive Cancer Network : JNCCN. 2004 Academic Article GET IT
Primary lymphoma of the breast: a case of marginal zone B-cell lymphoma. 2004 GET IT
Times cited: 5
New strategies in radioimmunotherapy for lymphoma. Current oncology reports. 2003 Academic Article GET IT
Times cited: 11
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003 Academic Article GET IT
Times cited: 220
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Review GET IT
Times cited: 98

more ...

less ...

Background

education and training

M.D., State University of New York Health Science Center at Brooklyn 1997
B.S., Duke University 1992

Contact

full name

Paul Hamlin

VIVO Weill Cornell Medical College

Paul Hamlin Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name